Deal Details
Antibody Analytics Recieves Investment From NorthEdge
Summary
Antibody Analytics Limited (“Antibody Analytics” or the “Company”) has received a minority strategic investment from NorthEdge Capital (“NorthEdge”). Terms of the transaction were not disclosed.
Baird served as the exclusive financial advisor to Antibody Analytics on this transaction.
About
Antibody Analytics stands at the intersection of cutting-edge research and customer-centric services in the field of pre-clinical drug discovery. The Company supports biopharmaceutical companies globally to overcome substantial scientific challenges by providing data of outstanding quality to expedite new healthcare solutions and improve global health outcomes. Antibody Analytics is focused on supporting the developers of antibody-targeted therapeutics, complex biologics and immunotherapies to help their clients get the best drug candidates into the clinic. Antibody Analytics is headquartered in Motherwell, Scotland.NorthEdge is a lower mid-market private equity firm, owned and built by its senior team, supported by a global blue chip investor base. It has £900m AUM across four regionally focused funds. With offices in Manchester, Leeds and Birmingham, the NorthEdge team has a 25-year track record of investing in businesses with ambitious management teams and significant growth potential. NorthEdge looks to invest in like-minded businesses and management teams who have real ambition and the potential to shape global markets. They back management teams in the Technology, Healthcare, Business Services and Specialised Industrials sectors who recognise the value of having an experienced business partner alongside them to build a better business. NorthEdge is headquartered in Manchester, England.
CONTACT US TO LEARN MORE
- Date
- November 2023
- Company
- Antibody Analytics Limited
- Transaction
- M&A - Sellside
- Sectors
- Healthcare
- Verticals
-
Pharmaceutical Services
- Target Geography
- Europe
- Acquiror Geography
- Europe
Share
